中恒集团：深耕医药制造 上半年营收净利同比双增

Core Insights - Zhongheng Group reported a revenue of 1.451 billion yuan for the first half of 2025, representing a year-on-year increase of 2.84%, while net profit attributable to shareholders reached 27.08 million yuan, up 23.59% year-on-year, and net profit after deducting non-recurring gains and losses was 24.83 million yuan, showing a significant increase of 196.24% [1][2] Group 1 - The company strengthened market expansion efforts and increased investment in R&D, leading to growth in both revenue and net profit [1] - Zhongheng Group focused on its core pharmaceutical manufacturing business, maintaining market share for key products, with sales of injectable thrombolytic agents and traditional Chinese medicine products both showing year-on-year growth [1][2] Group 2 - The company optimized its R&D system and established incentive management measures, signing cooperation agreements with key laboratories to enhance innovation capabilities [2] - Zhongheng Group concentrated on key therapeutic areas such as cardiovascular and chronic kidney disease, advancing key research projects and new drug initiatives [2] Group 3 - The company utilized the natural advantages of Guangxi's specialty medicinal materials, showing strong market potential in health consumption and daily chemical beauty sectors, with a product matrix already established [2] - In the health consumption sector, the subsidiary launched 26 new products, while the daily chemical beauty sector developed a dual innovation matrix combining technology and products [2] Group 4 - To protect the interests of the company and its investors, Zhongheng Group repurchased shares worth 301 million yuan, totaling 118 million shares, which accounted for 3.56% of the total share capital, completed on August 27 [3]